25 August 2021 - Availability in the U.S. expected shortly supported by a full suite of patient support programs.
Ascendis Pharma today announced that the U.S. FDA has approved Skytrofa (lonapegsomatropin-tcgd) for the treatment of paediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone.